|
SLC9A6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.39699999971377E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.37839999994716E-06 |
| Normal-vs-Stage2 |
5.821400E-03 |
| Normal-vs-Stage3 |
3.76250000000411E-05 |
| Normal-vs-Stage4 |
5.10859999969249E-07 |
| Stage1-vs-Stage2 |
5.053400E-01 |
| Stage1-vs-Stage3 |
6.386800E-01 |
| Stage1-vs-Stage4 |
8.557600E-02 |
| Stage2-vs-Stage3 |
3.865400E-01 |
| Stage2-vs-Stage4 |
6.221500E-02 |
| Stage3-vs-Stage4 |
1.937250E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.81569999994025E-07 |
| Normal-vs-AfricanAmerican |
5.187600E-02 |
| Normal-vs-Asian |
2.160900E-04 |
| Caucasian-vs-AfricanAmerican |
3.187400E-01 |
| Caucasian-vs-Asian |
9.482800E-01 |
| AfricanAmerican-vs-Asian |
3.617600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.61617999999697E-05 |
| Normal-vs-Female |
1.72970000000827E-06 |
| Male-vs-Female |
7.751800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.50454999999772E-05 |
| Normal-vs-Age(41-60Yrs) |
3.5497000000495E-06 |
| Normal-vs-Age(61-80Yrs) |
2.385500E-04 |
| Normal-vs-Age(81-100Yrs) |
4.441700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.593400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.421000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.816400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.540000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.642200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.366600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.047240E-01 |
| Classical-VS-Follicular |
4.689800E-01 |
| Classical-VS-Other |
4.045400E-01 |
| Classical-VS-Normal |
4.16069999999991E-05 |
| Tall-VS-Follicular |
3.235200E-01 |
| Tall-VS-Other |
9.996800E-01 |
| Tall-VS-Normal |
3.61440000000712E-05 |
| Follicular-VS-Other |
5.960400E-01 |
| Follicular-VS-Normal |
2.563800E-04 |
| Other-VS-Normal |
2.725800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.16069999999791E-05 |
| Normal-vs-N1 |
1.91060000043208E-07 |
| N0-vs-N1 |
4.568100E-02 |
|
|
